Cover Image
市場調查報告書

美國的免疫學的醫藥品市場產品系列

US Market Product Portfolio for Immunology Drugs 2018 - MedFolio

出版商 iData Research Inc. 商品編碼 573090
出版日期 內容資訊 英文 987 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的免疫學的醫藥品市場產品系列 US Market Product Portfolio for Immunology Drugs 2018 - MedFolio
出版日期: 2017年10月01日 內容資訊: 英文 987 Pages
簡介

本報告提供美國的免疫學的醫藥品市場相關調查分析,市場概要,產品的評估,企業簡介等系統性資訊。

摘要整理

市場概要

競爭情形

市場趨勢

市場發展

第1章 對象市場

  • 版本履歷

第2章 調查手法

第3章 作用機制

  • 簡介

第4章 產品的評估

  • 主要上市產品
  • 主要的開發中產品
  • 開發中的產品:各主要企業
  • 臨床試驗:各疾病

第5章 國家概況

  • 美國

第6章 企業簡介

  • ABBVIE INC.
  • AMGEN INC.
  • BIOGEN IDEC
  • BRISTOL-MYERS SQUIBB
  • HOFFMANN-LA ROCHE LTD
  • JOHNSON & JOHNSON/JANSSEN
  • NOVARTIS AG
  • PFIZER INC.
  • 武田藥品工業
  • UCB S.A.

簡稱

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_USIM18_MF

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

The full report suite is an extensive market analysis study on the current biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI ®. The others segment includes XELJANZ®, promising biologics in pipeline consisting of JAK inhibitors (imposing competition to XELJANZ®) and other TNF and interleukin biologics that will enter the market during the forecast period.

Some of these biologics are approved and used in more than one conditions. Therefore, the market is segmented by diseases. The report comprises market analyses on rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis and psoriasis drugs globally.

TABLE OF CONTENTS I

LIST OF FIGURES XXVIII

LIST OF CHARTS XXXVII

EXECUTIVE SUMMARY 1

MARKET OVERVIEW 1

COMPETITIVE LANDSCAPE 3

MARKET TRENDS 5

KEY MARKET DEVELOPMENTS 6

MARKETS INCLUDED 12

  • 1.1 VERSION HISTORY 13

IDATA PHARMA'S 9-STEP METHODOLOGY 14

    • Step 1: Project Initiation & Team Selection 14
    • Step 2: Prepare Data Systems and Perform Secondary Research 17
    • Step 3: Preparation for Interviews & Questionnaire Design 19
    • Step 4: Performing Primary Research 20
    • Step 5: Research Analysis: Establishing Baseline Estimates 22
    • Step 6: Market Forecasts and Analysis 24
    • Step 7: Identify Strategic Opportunities 26
    • Step 8: Final Review and Market Release 27
    • Step 9: Customer Feedback and Market Monitoring 28

MECHANISM OF ACTION 29

  • 3.1 INTRODUCTION 29
    • 3.1.1 Tumor Necrosis Factor (TNF) 32
    • 3.1.2 B-cell Inhibitors 32
    • 3.1.3 Interleukin Inhibitors 32
    • 3.1.4 Janus Kinase Inhibitors 32
    • 3.1.5 Co-stimulation Modulators 33

PRODUCT ASSESSMENT 34

  • 4.1 KEY MARKETED PRODUCTS 34
    • 4.1.1 Abatacept (ORENCIA®) 34
      • 4.1.1.1 Future Developments 34
      • 4.1.1.2 Currently Marketed Products by Company 36
    • 4.1.2 Adalimumab (HUMIRA®) 37
      • 4.1.2.1 Future Developments 38
      • 4.1.2.2 Currently Marketed Products by Company 40
    • 4.1.3 Certolizumab pegol (CIMZIA®) 41
      • 4.1.3.1 Future Developments 41
      • 4.1.3.2 Currently Marketed Products by Company 42
    • 4.1.4 Etanercept (ENBREL®, Benepali®) 43
      • 4.1.4.1 Future Developments 44
      • 4.1.4.2 Currently Marketed Products by company 46
    • 4.1.5 Golimumab (SIMPONI®) 47
      • 4.1.5.1 Future Developments 47
      • 4.1.5.2 Currently Marketed Products by company 48
    • 4.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®) 49
      • 4.1.6.1 Future Developments 50
      • 4.1.6.2 Currently Marketed Products by company 51
    • 4.1.7 Natalizumab (TYSABRI®) 52
      • 4.1.7.1 Currently Marketed Products by company 53
    • 4.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™) 54
      • 4.1.8.1 Future Developments 54
      • 4.1.8.2 Currently Marketed Products by company 56
    • 4.1.9 Tocilizumab (Actemra®/RoActemra®) 57
      • 4.1.9.1 Currently Marketed Products by company 58
    • 4.1.10 Tofacitinib (XELJANZ®) 59
      • 4.1.10.1 Future Developments 59
      • 4.1.10.2 Currently Marketed Products by company 61
    • 4.1.11 Ustekinumab (STELARA®) 62
      • 4.1.11.1 Future Developments 62
      • 4.1.11.2 Currently Marketed Products by company 63
    • 4.1.12 Vedolizumab (ENTYVIO®) 64
      • 4.1.12.1 Currently Marketed Products by company 65
  • 4.2 KEY PRODUCTS IN PIPELINE 66
    • 4.2.1 Barcitinb (Olumiant®) 66
    • 4.2.2 Guselkumab (Tremfya™) 66
    • 4.2.3 Cobitolimod (Kappaproct®) 66
    • 4.2.4 Mavrilimumab 67
    • 4.2.5 Sirukumab 67
    • 4.2.6 Vobarilizumab 68
  • 4.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES 70
  • 4.4 CLINICAL TRIAL BY DISEASE 75
    • 4.4.1 Rheumatoid Arthritis 76
      • 4.4.1.1 Study Completion Date: 2017 76
      • 4.4.1.2 Study Completion Date: 2016 80
    • 4.4.2 Crohn's Disease (CD) 95
      • 4.4.2.1 Study Completion Date: 2017 95
      • 4.4.2.2 Study Completion Date: 2016 96
      • 4.4.2.3 Study Completion Date: 2015 98
    • 4.4.3 Ankylosing Spondylitis (AS) 101
      • 4.4.3.1 Study Completion Date: 2017 101
      • 4.4.3.2 Study Completion Date: 2016 101
      • 4.4.3.3 Study Completion Date: 2015 102
    • 4.4.4 Psoriasis (Ps) 104
      • 4.4.4.1 Study Completion Date: 2017 104
      • 4.4.4.2 Study Completion Date: 2016 108
    • 4.4.5 Ulcerative Colitis (UC) 118
      • 4.4.5.1 Study Completion Date: 2016 118
      • 4.4.5.2 Study Completion Date: 2015 122

COUNTRY PROFILE 125

  • 5.1 UNITED STATES 125
    • 5.1.1 Population and Demographics 125
    • 5.1.2 Treatment Size Analysis for 2017 125
    • 5.1.3 Drug Cost Analysis 128

COMPANY PROFILES 131

  • 6.1 ABBVIE INC. 131
    • 6.1.1 Business Overview 131
    • 6.1.2 Financials 133
    • 6.1.3 SWOT Analysis 134
      • 6.1.3.1 Strengths: 134
      • 6.1.3.2 Weakness: 135
      • 6.1.3.3 Opportunity: 135
      • 6.1.3.4 Threats: 136
  • 6.2 AMGEN INC. 138
    • 6.2.1 Business Overview 138
    • 6.2.2 Financials 139
    • 6.2.3 SWOT Analysis 140
      • 6.2.3.1 Strengths: 140
      • 6.2.3.2 Weaknesses: 141
      • 6.2.3.3 Opportunities: 142
      • 6.2.3.4 Threats: 143
  • 6.3 BIOGEN IDEC 145
    • 6.3.1 Business Overview 145
    • 6.3.2 Financials 146
    • 6.3.3 SWOT Analysis 147
      • 6.3.3.1 Strengths: 147
      • 6.3.3.2 Weakness: 148
      • 6.3.3.3 Opportunities: 148
      • 6.3.3.4 Threats: 150
  • 6.4 BRISTOL-MYERS SQUIBB 151
    • 6.4.1 Business Overview 151
    • 6.4.2 Financials 152
    • 6.4.3 SWOT Analysis 154
      • 6.4.3.1 Strengths: 154
      • 6.4.3.2 Weakness: 155
      • 6.4.3.3 Opportunities: 155
      • 6.4.3.4 Threats: 157
  • 6.5 HOFFMANN-LA ROCHE LTD 159
    • 6.5.1 Business Overview 159
    • 6.5.2 Financials 160
    • 6.5.3 SWOT Analysis 161
      • 6.5.3.1 Strengths: 161
      • 6.5.3.2 Weakness: 162
      • 6.5.3.3 Opportunities: 163
      • 6.5.3.4 Threats: 163
  • 6.6 JOHNSON & JOHNSON/JANSSEN 165
    • 6.6.1 Business Overview 165
    • 6.6.2 Financials 166
    • 6.6.3 SWOT Analysis 167
      • 6.6.3.1 STRENGTHS: 167
      • 6.6.3.2 Weakness: 168
      • 6.6.3.3 Opportunities: 169
      • 6.6.3.4 Threats: 170
  • 6.7 NOVARTIS AG 172
    • 6.7.1 Business Overview 172
    • 6.7.2 Financials 173
    • 6.7.3 SWOT Analysis 174
      • 6.7.3.1 STRENGTHS: 174
      • 6.7.3.2 Weakness: 175
      • 6.7.3.3 Opportunities: 175
      • 6.7.3.4 Threats: 177
  • 6.8 PFIZER INC. 178
    • 6.8.1 Business Overview 178
    • 6.8.2 Financials 179
    • 6.8.3 SWOT Analysis 180
      • 6.8.3.1 Strengths: 180
      • 6.8.3.2 Weakness 181
      • 6.8.3.3 Opportunities 182
      • 6.8.3.4 Threats: 183
  • 6.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 185
    • 6.9.1 Business Overview 185
    • 6.9.2 Financials 186
    • 6.9.3 SWOT Analysis 187
      • 6.9.3.1 Strengths: 187
      • 6.9.3.2 Weakness: 188
      • 6.9.3.3 Opportunities 188
      • 6.9.3.4 Threats: 190
  • 6.10 UCB S.A. 192
    • 6.10.1 Business Overview 192
    • 6.10.2 Financials 193
    • 6.10.3 SWOT Analysis 194
      • 6.10.3.1 Strengths: 194
      • 6.10.3.2 Weakness: 195
      • 6.10.3.3 Opportunities: 195
      • 6.10.3.4 Threats: 196

ABBREVIATIONS 197

APPENDIX: COMPANY PRESS RELEASES 200

LIST OF CHARTS

  • Chart 2 1: Immunology Market by Segment, U.S., 2013 - 2023 2
  • Chart 2 2: Immunology Market Overview, U.S., 2016 & 2023 2
  • Chart 6 1: Enbrel® Revenue, 2012-2016 141

LIST OF FIGURES

  • Figure 2 1: Immunology Market Share Ranking by Segment, U.S., 2017 3
  • Figure 2 2: Companies Researched in this Report, U.S., 2017 4
  • Figure 2 3: Factors Impacting the Immunology Market 5
  • Figure 2 4: Recent Events in the Immunology Market, Global, 2016 - 2017, AbbVie 6
  • Figure 2 5: Recent Events in the Immunology Market, Global, 2016 - 2017, Amgen 6
  • Figure 2 6: Recent Events in the Immunology Market, Global, 2016 - 2017, AstraZeneca 7
  • Figure 2 7: Recent Events in the Immunology Market, Global, 2016 - 2017, Biogen 7
  • Figure 2 8: Recent Events in the Immunology Market, Global, 2016 - 2017, BMS 7
  • Figure 2 9: Recent Events in the Immunology Market, Global, 2016 - 2017, Eli Lilly 8
  • Figure 2 10: Recent Events in the Immunology Market, Global, 2016 - 2017, Roche 8
  • Figure 2 11: Recent Events in the Immunology Market, Global, 2016 - 2017, Janssen 9
  • Figure 2 12: Recent Events in the Immunology Market, Global, 2016 - 2017, Merck 9
  • Figure 2 13: Recent Events in the Immunology Market, Global, 2016 - 2017, Merck 10
  • Figure 2 14: Recent Events in the Immunology Market, Global, 2016 - 2017, Pfizer 11
  • Figure 2 15: Recent Events in the Immunology Market, Global, 2016 - 2017, Takeda 11
  • Figure 2 16: Recent Events in the Immunology Market, Global, 2016 - 2017, UCB 11
  • Figure 2 17: Immunology Markets Covered, U.S., 2016 (1 of 2) 12
  • Figure 2 18: Immunology Markets Covered, U.S., 2016 (2 of 2) 13
  • Figure 2 19: Version History 13
  • Figure 3 1: Classification by Mechanism of Action 31
  • Figure 4 1: Marketed Product Portfolio by Company 36
  • Figure 4 2: Marketed Product Portfolio by Company 40
  • Figure 4 3: Marketed Product Portfolio by Company 42
  • Figure 4 4: Marketed Product Portfolio by Company 46
  • Figure 4 5: Marketed Product Portfolio by Company 48
  • Figure 4 6: Marketed Product Portfolio by Company 51
  • Figure 4 7: Marketed Product Portfolio by Company 53
  • Figure 4 8: Marketed Product Portfolio by Company 56
  • Figure 4 9: Marketed Product Portfolio by Company 58
  • Figure 4 10: Marketed Product Portfolio by Company 61
  • Figure 4 11: Marketed Product Portfolio by Company 63
  • Figure 4 12: Marketed Product Portfolio by Company 65
  • Figure 4 13: Other products in pipeline 69
  • Figure 4 14: Pipeline Product Portfolio by Company (1 of 5) 70
  • Figure 4 15: Pipeline Product Portfolio by Company (2 of 5) 71
  • Figure 4 16: Pipeline Product Portfolio by Company (3 of 5) 72
  • Figure 4 17: Pipeline Product Portfolio by Company (4 of 5) 73
  • Figure 4 18: Pipeline Product Portfolio by Company (5 of 5) 74
  • Figure 4 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA) 76
  • Figure 4 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS) 76
  • Figure 4 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE) 77
  • Figure 4 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis 77
  • Figure 4 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA 78
  • Figure 4 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis 78
  • Figure 4 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis 79
  • Figure 4 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab) 79
  • Figure 4 27: Abatacept Post-marketing Clinical Study in Japan 80
  • Figure 4 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY) 80
  • Figure 4 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) 81
  • Figure 4 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE) 81
  • Figure 4 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) 82
  • Figure 4 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis 82
  • Figure 4 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis 83
  • Figure 4 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis 83
  • Figure 4 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. 84
  • Figure 4 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis 84
  • Figure 4 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT) 85
  • Figure 4 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI) 85
  • Figure 4 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs 86
  • Figure 4 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study 86
  • Figure 4 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H) 87
  • Figure 4 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent 87
  • Figure 4 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants 88
  • Figure 4 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC) 88
  • Figure 4 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT) 89
  • Figure 4 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects 89
  • Figure 4 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C) 90
  • Figure 4 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR) 90
  • Figure 4 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02) 91
  • Figure 4 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis 91
  • Figure 4 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis 92
  • Figure 4 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors 92
  • Figure 4 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY) 93
  • Figure 4 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis 93
  • Figure 4 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) 94
  • Figure 4 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate 94
  • Figure 4 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 95
  • Figure 4 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease 95
  • Figure 4 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA) 96
  • Figure 4 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM) 96
  • Figure 4 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) 97
  • Figure 4 62: Adalimumab-psoriasis and Small Bowel Lesions 97
  • Figure 4 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas 98
  • Figure 4 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease 98
  • Figure 4 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) 99
  • Figure 4 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease 99
  • Figure 4 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA) 100
  • Figure 4 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis 101
  • Figure 4 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis 101
  • Figure 4 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis 102
  • Figure 4 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS) 102
  • Figure 4 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY) 103
  • Figure 4 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD) 103
  • Figure 4 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) 104
  • Figure 4 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis 104
  • Figure 4 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis 105
  • Figure 4 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA® 105
  • Figure 4 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR) 106
  • Figure 4 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim) 106
  • Figure 4 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO) 107
  • Figure 4 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE) 107
  • Figure 4 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE) 108
  • Figure 4 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE) 108
  • Figure 4 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE) 109
  • Figure 4 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN) 109
  • Figure 4 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E) 110
  • Figure 4 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis 110
  • Figure 4 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS) 111
  • Figure 4 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE) 111
  • Figure 4 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis 112
  • Figure 4 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME) 112
  • Figure 4 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A 113
  • Figure 4 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) 113
  • Figure 4 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE) 114
  • Figure 4 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis 114
  • Figure 4 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA) 115
  • Figure 4 97: Adalimumab-psoriasis and Small Bowel Lesions 115
  • Figure 4 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND) 116
  • Figure 4 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) 116
  • Figure 4 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS) 117
  • Figure 4 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis 117
  • Figure 4 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis 118
  • Figure 4 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3) 118
  • Figure 4 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE) 119
  • Figure 4 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS) 119
  • Figure 4 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) 120
  • Figure 4 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis 120
  • Figure 4 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP) 121
  • Figure 4 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART) 122
  • Figure 4 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients 122
  • Figure 4 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE) 123
  • Figure 4 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE) 123
  • Figure 4 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda) 124
  • Figure 4 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis 124
  • Figure 5 1: Prevalence of the autoimmune diseases in the U.S., 2017 125
  • Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017 126
  • Figure 5 3: Treatment Population Size of Crohn's Disease, U.S., 2017 126
  • Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017 126
  • Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017 127
  • Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017 127
  • Figure 5 7: List of U.S. Retail Pharmacies 128
  • Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2) 129
  • Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2) 129
  • Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S. 130
  • Figure 6 1: Key Facts, AbbVie Inc., 2017 131
  • Figure 6 2: Financials, AbbVie Inc., 2017 133
  • Figure 6 3: SWOT Analysis, AbbVie Inc., 2017 134
  • Figure 6 4: Key Facts, Amgen, 2017 138
  • Figure 6 5: Financial Overview, Amgen, 2017 139
  • Figure 6 6: SWOT Analysis, Amgen, 2017 140
  • Figure 6 7: Patent Expiries, Enbrel® 141
  • Figure 6 8: Key Facts, Biogen Idec 145
  • Figure 6 9: Financials, Biogen Idec, 2017 146
  • Figure 6 10: SWOT Analysis, Biogen Idec 147
  • Figure 6 11: Key Facts, Bristol-Myers Squibb 151
  • Figure 6 12: Financials, Bristol-Myers Squibb, 2017 152
  • Figure 6 13: Bristol-Myers Squibb, Key Products Revenue (US$M) 153
  • Figure 6 14: SWOT Analysis, Bristol-Myers Squibb 154
  • Figure 6 15: Key Facts, Hoffman-La Roche Ltd 159
  • Figure 6 16: Financials, Hoffman-La Roche Ltd , 2017 160
  • Figure 6 17: SWOT Analysis, Hoffman-La Roche Ltd 161
  • Figure 6 18: Key Facts, Johnson & Johnson 165
  • Figure 6 19: Financials, Johnson & Johnson, 2017 166
  • Figure 6 20: SWOT Analysis, Johnson & Johnson 167
  • Figure 6 21: Key Facts, Novartis AG 172
  • Figure 6 22: Financials, Novartis AG, 2017 173
  • Figure 6 23: SWOT Analysis, Novartis AG 174
  • Figure 6 24: Key Facts, Pfizer Inc. 178
  • Figure 6 25: Financials, Pfizer Inc., 2017 179
  • Figure 6 26: SWOT Analysis, Pfizer Inc. 180
  • Figure 6 27: Key Facts, Takeda Pharmaceutical Company Limited 185
  • Figure 6 28: Financials, Takeda Pharmaceutical Company Limited , 2017 186
  • Figure 6 29: SWOT Analysis, Takeda Pharmaceutical Company Limited 187
  • Figure 6 30: Key Facts, UCB S.A. 192
  • Figure 6 31: Financials, UCB S.A., 2017 193
  • Figure 6 32: SWOT Analysis, UCB S.A. 194
  • Figure 8 1: Press Release Summary 200
Back to Top